Panbela Therapeutics, Inc. (PBLA)

0.4000 -0.0400 (-9.09%) As of 11:20AM EDT. Market open.

Panbela Therapeutics, Inc.

712 Vista Boulevard
Suite 305
Waconia, MN 55387
United States
952 479 1196
https://www.panbela.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 7

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.	CEO, President & Director	527k	N/A	1968
Ms. Susan Horvath	VP of Finance, CFO, Secretary & Treasurer	452.39k	N/A	1959
Ms. Tammy Groene	Vice President of Operations	N/A	N/A	N/A
Dr. Elizabeth Bruckheimer Ph.D.	VP & Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Corporate Governance

Panbela Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.